Hormone Therapy Linked to Greater Weight Loss With Semaglutide

Findings From the Menopause Society Annual Meeting

Midlife women taking hormone therapy (HT) alongside semaglutide experienced greater and sustained weight reduction compared to peers taking the medication alone. Researchers presented the data at the 2026 Annual Meeting of The Menopause Society in San Diego. The investigation analyzed real-world clinical records from women older than 45 years with a body mass index (BMI) above 27 kg/m².

Women between ages 50 and 64 represent the largest group of glucagon-like peptide-1 (GLP-1) users in the United States. Federal data cited in the presentation shows that one in five women in this bracket reports current or previous use of a GLP-1 medication. While aging drives many midlife physical changes, the menopause transition independently contributes to fat accumulation and shifts in body composition.

Comparing Outcomes Between Semaglutide and Tirzepatide

Hormone therapy was associated with sustained weight loss for semaglutide users, but it failed to show a statistically significant long-term benefit for tirzepatide users. Semaglutide targets the GLP-1 receptor alone. Tirzepatide targets both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors.

Patients taking tirzepatide alongside hormone therapy initially lost more weight than non-users, yet that gap narrowed over follow-up until it lacked statistical significance. Lead author Dr. Regina Castaneda from Mayo Clinic Florida noted that the stronger interaction seen with semaglutide points to a mechanism tied specifically to GLP-1 signaling pathways.

• Nearly 2,400 women evaluated on semaglutide
• Nearly 1,500 women evaluated on tirzepatide
• All participants were over age 45 with a body mass index above 27 kg/m²

Biological Plausibility and Earlier Observational Research

Preclinical evidence indicates that estrogen signaling and GLP-1 pathways interact directly to regulate metabolic function. Dr. Castaneda explained that this biological plausibility supports the clinical observations. Earlier, smaller observational studies in postmenopausal groups had noted a similar link between hormone therapy and enhanced weight loss on both medications.

Medical director for The Menopause Society Dr. Stephanie Faubion stated that reproductive stage influences how individuals metabolize and respond to obesity therapies. Female sex and younger age generally correlate with stronger responses to GLP-1 therapies. Tracking hormonal status helps clinicians understand why weight-loss trajectories vary substantially among midlife patients.

Study Limitations and Practical Clinical Context

Retrospective observational data cannot prove that hormone therapy causes increased weight loss during GLP-1 treatment. Unmeasured lifestyle factors, variations in baseline health, and differences in treatment adherence could account for the observed separation between the groups. Dr. Castaneda noted that researchers must confirm these outcomes in prospective, randomized clinical trials before changing practice guidelines.

Hormone therapy is approved for managing vasomotor symptoms and other menopause-related conditions. It is not approved as an adjunct drug for obesity management. Patients reviewing these findings should discuss their menopausal symptoms and metabolic therapy with their personal healthcare provider rather than seeking hormone prescriptions for body-weight changes.